General Info

Lixte Biotechnology Holdings is a publicly traded therapeutic and diagnostics company that focuses on the improvement of treatment options for life-threatening cancers. The company undertakes various biomedical research activities for the development of drugs for cancers. Founded in 2005, Lixte Biotechnology Holdings is engaged in the development of chemotherapy drugs that target molecular abnormalities of cancers in humans. Based on the discovery of biomarkers for brain cancers by collaborators at the National Institutes of Health, the company evaluates drugs for the treatment of cancer in adults and children. It works in partnership with the National Institute of Neurological Disorders and Stroke to study the effectiveness of lead compounds.